NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.00 -0.05 (-0.45 %)
(As of 07/18/2018 02:19 PM ET)
Previous Close$11.00
Today's Range$10.55 - $11.00
52-Week Range$7.46 - $18.00
Volume4,129 shs
Average Volume74,513 shs
Market Capitalization$118.05 million
P/E Ratio-2.23
Dividend YieldN/A
Beta1.82
Eiger Biopharmaceuticals logoEiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-279-9845

Debt

Debt-to-Equity Ratio0.81
Current Ratio4.51
Quick Ratio4.51

Price-To-Earnings

Trailing P/E Ratio-2.23
Forward P/E Ratio-3.59
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book5.14

Profitability

EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-227.27%
Return on Assets-105.48%

Miscellaneous

Employees16
Outstanding Shares10,540,000
Market Cap$118.05

The Truth About Cryptocurrencies

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.96) by $0.12. View Eiger Biopharmaceuticals' Earnings History.

What price target have analysts set for EIGR?

7 equities research analysts have issued twelve-month price objectives for Eiger Biopharmaceuticals' stock. Their forecasts range from $24.00 to $39.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $30.8571 in the next year. This suggests a possible upside of 180.5% from the stock's current price. View Analyst Ratings for Eiger Biopharmaceuticals.

What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Eiger Biopharmaceuticals' key competitors?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 54)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 55)
  • Mr. James A. Welch, Chief Financial Officer (Age 60)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 53)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 51)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

Media stories about EIGR stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 0.16 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.60 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $11.00.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $118.05 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.